MX2017013729A - Deteccion especifica de isoformas de clusterina. - Google Patents

Deteccion especifica de isoformas de clusterina.

Info

Publication number
MX2017013729A
MX2017013729A MX2017013729A MX2017013729A MX2017013729A MX 2017013729 A MX2017013729 A MX 2017013729A MX 2017013729 A MX2017013729 A MX 2017013729A MX 2017013729 A MX2017013729 A MX 2017013729A MX 2017013729 A MX2017013729 A MX 2017013729A
Authority
MX
Mexico
Prior art keywords
specific detection
clusterin isoforms
clusterin
isoforms
detection
Prior art date
Application number
MX2017013729A
Other languages
English (en)
Other versions
MX388832B (es
Inventor
Joseph Quinn John
VSN YERRAMILLI Murthy
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Publication of MX2017013729A publication Critical patent/MX2017013729A/es
Publication of MX388832B publication Critical patent/MX388832B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/521—Single-layer analytical elements
    • G01N33/523—Single-layer analytical elements the element being adapted for a specific analyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención proporciona métodos y composiciones para la detección de isoformas específicas de clusterina.
MX2017013729A 2015-04-30 2016-04-29 Deteccion especifica de isoformas de clusterina. MX388832B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562155175P 2015-04-30 2015-04-30
PCT/US2016/030075 WO2016176565A1 (en) 2015-04-30 2016-04-29 Specific detection of clusterin isoforms

Publications (2)

Publication Number Publication Date
MX2017013729A true MX2017013729A (es) 2018-05-22
MX388832B MX388832B (es) 2025-03-20

Family

ID=56069221

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013729A MX388832B (es) 2015-04-30 2016-04-29 Deteccion especifica de isoformas de clusterina.

Country Status (12)

Country Link
US (1) US20180142009A1 (es)
EP (2) EP4019976A1 (es)
JP (2) JP6948265B2 (es)
KR (1) KR102462056B1 (es)
CN (1) CN108093648B (es)
AU (1) AU2016254150B2 (es)
CA (1) CA2983828A1 (es)
DK (1) DK3289363T3 (es)
ES (1) ES2907068T3 (es)
MX (1) MX388832B (es)
WO (1) WO2016176565A1 (es)
ZA (1) ZA201707313B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4019976A1 (en) * 2015-04-30 2022-06-29 Idexx Laboratories, Inc. Specific detection of clusterin isoforms
EP3232200A1 (en) * 2016-04-12 2017-10-18 Institut Catalá De Ciencies Cardiovasculars (ICCC) Methods and kits for the diagnosis and risk stratification of patients with ischemia
FR3069156B1 (fr) * 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
CN109239362B (zh) * 2018-10-22 2021-05-07 西北大学 一种凝集素探针组合在基于尿蛋白糖型鉴别秦岭川金丝猴妊娠方面的应用
CN110045127A (zh) * 2019-04-03 2019-07-23 中国医学科学院北京协和医院 一种IgG4相关性疾病多器官受累的生物标志物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
JP2714664B2 (ja) * 1988-04-13 1998-02-16 塩野義製薬株式会社 マイコプラズマ由来マクロファージ活性化因子
US5726010A (en) 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
WO2004005934A2 (en) * 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
ITRM20040098A1 (it) * 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
US7776550B2 (en) * 2005-05-05 2010-08-17 Philadelphia Health & Education Corporation Diagnosis of liver pathology through assessment of protein glycosylation
CN102264230B (zh) * 2008-11-10 2014-12-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
WO2010132447A2 (en) * 2009-05-11 2010-11-18 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
EP2668497B1 (en) * 2011-01-26 2020-03-25 University of Pittsburgh - Of the Commonwealth System of Higher Education Urine biomarkers for prediction of recovery after acute kidney injury : proteomics
CN105556305A (zh) * 2013-06-05 2016-05-04 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN104267187A (zh) * 2014-10-15 2015-01-07 吉林大学 检测尿液Clusterin含量试纸条的制备及应用
EP4019976A1 (en) * 2015-04-30 2022-06-29 Idexx Laboratories, Inc. Specific detection of clusterin isoforms

Also Published As

Publication number Publication date
EP4019976A1 (en) 2022-06-29
CA2983828A1 (en) 2016-11-03
AU2016254150A1 (en) 2017-10-26
EP3289363B1 (en) 2021-11-24
CN108093648A (zh) 2018-05-29
BR112017021850A2 (pt) 2018-07-10
US20180142009A1 (en) 2018-05-24
CN108093648B (zh) 2020-04-10
JP2018515762A (ja) 2018-06-14
JP6948265B2 (ja) 2021-10-13
NZ736200A (en) 2021-11-26
AU2016254150B2 (en) 2021-09-30
ES2907068T3 (es) 2022-04-21
KR102462056B1 (ko) 2022-11-02
ZA201707313B (en) 2022-02-23
KR20180003549A (ko) 2018-01-09
JP2021099342A (ja) 2021-07-01
MX388832B (es) 2025-03-20
EP3289363A1 (en) 2018-03-07
WO2016176565A1 (en) 2016-11-03
DK3289363T3 (da) 2022-02-28

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
MX384884B (es) Inhibidores de ret.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
MX379270B (es) Composiciones que comprenden cepas bacterianas.
MX378686B (es) Composiciones que comprenden cepas bacterianas.
CR20190271A (es) Anticuerpos antitau y métodos de uso
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
PT3204015T (pt) Composições e métodos para inibição de expressão do gene hao1 (hidroxiácido oxidase 1 (glicolato oxidase))
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX388752B (es) Composiciones novedosas, usos y métodos para hacerlas.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
MX374654B (es) Compuestos útiles para inhibir ror-gamma-t.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
BR112017013928A2 (pt) composição alimentar e método de uso.